Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy-Reference-Cited by-同舟云学术

Minimal residual disease undetectable by next-generation sequencing predicts improved outcome in CLL after chemoimmunotherapy

Published:2019-11-28 Issue:22 Volume:134 Page:1951-1959
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Thompson Philip A.¹^ORCID,Srivastava Jaya²,Peterson Christine³^ORCID,Strati Paolo¹,Jorgensen Jeffrey L.⁴,Hether Tyler²,Keating Michael J.¹,O’Brien Susan M.⁵,Ferrajoli Alessandra¹,Burger Jan A.¹^ORCID,Estrov Zeev¹^ORCID,Jain Nitin¹,Wierda William G.¹

Affiliation:

1. Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX;

2. Adaptive Biotechnologies Corporation, Seattle, WA;

3. Department of Biostatistics and

4. Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX; and

5. The Chao Comprehensive Cancer Center, University of California, Irvine, CA

Abstract

Thompson and colleagues report that detection of minimal residual disease using next-generation sequencing, which is 2 orders of magnitude more sensitive than flow cytometry, is a much better predictor of progression-free survival.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/134/22/1951/1543103/bloodbld2019001077.pdf

Reference36 articles.

1. Fludarabine, cyclophosphamide, and rituximab treatment achieves long-term disease-free survival in IGHV-mutated chronic lymphocytic leukemia;Thompson;Blood,2016

2. Molecular prediction of durable remission after first-line fludarabine-cyclophosphamide-rituximab in chronic lymphocytic leukemia;Rossi;Blood,2015

3. Long-term remissions after FCR chemoimmunotherapy in previously untreated patients with CLL: updated results of the CLL8 trial;Fischer;Blood,2016

4. Serial minimal residual disease (MRD) monitoring during first-line FCR treatment for CLL may direct individualized therapeutic strategies;Thompson;Leukemia,2018

5. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication;Bosch;Clin Cancer Res,2008

Cited by 52 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trial;Blood;2024-07-18

2. Measurable Residual Disease and Clinical Outcomes in Chronic Lymphocytic Leukemia;JAMA Oncology;2024-07-11

3. Defining treatment success in chronic lymphocytic leukemia: exploring surrogate markers, comorbidities, and patient-centered endpoints;Expert Review of Hematology;2024-06-13

4. Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy;Clinical Lymphoma Myeloma and Leukemia;2024-06

5. Monitoring Response and Resistance to Treatment in Chronic Lymphocytic Leukemia;Cancers;2024-05-28